The COVID-19 pandemic led to substantial declines in cancer incidence rates in 2020, likely because of disruptions in screening and diagnostic services. This study aimed to assess the impact of the pandemic on cancer incidence rates in the United States using 2021 incidence data from the Surveillance, Epidemiology, and End Results program. The analysis compared observed 2021 cancer incidence rates with expected prepandemic trends, evaluating changes by individual cancer site and stage. Although incidence overall and in many cancer sites the rates were close to prepandemic levels, they did not exhibit a recovery that incorporated the delayed diagnoses from 2020. There were exceptions, however, such as metastatic breast cancer, which showed significantly higher observed rates than expected (rate ratio = 1.09, 95% confidence interval = 1.04 to 1.13). Ongoing monitoring and targeted interventions are needed to address the long-term consequences of the COVID-19 pandemic on cancer care and outcomes.

中文翻译：

---

COVID-19 对 2021 年癌症发病率的影响以及 2020 年下降趋势的潜在反弹


COVID-19 大流行导致 2020 年癌症发病率大幅下降，这可能是因为筛查和诊断服务中断。本研究旨在利用监测、流行病学和最终结果计划的 2021 年发病率数据来评估大流行对美国癌症发病率的影响。该分析将观察到的 2021 年癌症发病率与预期的大流行前趋势进行比较，评估各个癌症部位和阶段的变化。尽管总体发病率和许多癌症部位的发病率接近大流行前的水平，但考虑到 2020 年以来的延迟诊断，这些发病率并未出现恢复。不过也有例外，例如转移性乳腺癌，其观察到的发病率明显高于预期（比率 = 1.09，95% 置信区间 = 1.04 至 1.13）。需要持续监测和有针对性的干预措施来解决 COVID-19 大流行对癌症护理和结果的长期影响。